Mediterranean Journal of Hematology and Infectious Diseases
Scope & Guideline
Connecting scholars to elevate hematology and infectious disease studies.
Introduction
Aims and Scopes
- Hematological Disorders:
The journal covers various hematological conditions including leukemias, lymphomas, myeloproliferative disorders, and anemias, focusing on their diagnosis, treatment, and management. - Infectious Diseases in Hematology:
Research on infectious complications in hematological patients, particularly those undergoing treatments like chemotherapy or stem cell transplantation, is a core focus. - Molecular and Genetic Studies:
The journal publishes studies on genetic predispositions, molecular alterations, and their implications for treatment strategies in hematological malignancies. - Innovative Therapies:
It highlights advancements in treatment modalities such as CAR-T cell therapy, monoclonal antibodies, and gene editing technologies for hematological diseases. - Real-World Evidence and Clinical Practice:
The journal emphasizes real-world studies and clinical outcomes to guide practice standards in hematology and infectious diseases. - Public Health and Epidemiology:
Research addressing the epidemiological aspects of hematological diseases and their interaction with public health issues, particularly in low-resource settings, is also featured.
Trending and Emerging
- Personalized Medicine and Genetic Profiling:
There is an increasing emphasis on personalized medicine, particularly the use of genetic profiling to tailor treatments for individual patients, especially in hematological malignancies. - CAR-T Cell Therapy and Immunotherapies:
Research on CAR-T cell therapies and other forms of immunotherapy is rapidly growing, reflecting a shift towards innovative treatments for hematological cancers. - Long-Term Outcomes and Survivorship Studies:
An emerging focus on the long-term outcomes of patients who have survived hematological malignancies, including quality of life and late effects of treatment. - Infectious Disease Management in Immunocompromised Patients:
There is a heightened interest in managing infectious diseases specifically in immunocompromised patients, particularly those undergoing hematological treatments. - Health Disparities and Global Health:
Research addressing health disparities, particularly in low-resource settings, is becoming more prominent, focusing on access to care and treatment outcomes. - Integration of Technology in Treatment:
The application of technology, such as telemedicine and digital health tools, in monitoring and managing patients with hematological disorders is gaining traction.
Declining or Waning
- Traditional Chemotherapy Approaches:
There has been a noticeable reduction in studies focusing solely on traditional chemotherapy regimens without combination therapies, as newer treatment modalities gain preference. - Basic Laboratory Techniques:
Research centered around basic laboratory methods and techniques has decreased, likely overshadowed by the growing complexity and specificity of molecular and genetic studies. - Infectious Disease Studies Outside Hematology:
The focus on infectious diseases that are not specifically related to hematology, such as general epidemiological studies, seems to be waning in favor of more targeted research within hematological contexts. - Single-Center Studies:
There is a decline in the publication of single-center studies, as there is a growing trend towards multicenter collaborations that provide broader, more generalizable findings. - Aging and General Health Studies:
Research focusing on general health issues and aging populations, unless directly related to hematological conditions, appears to be less frequent in recent publications.
Similar Journals
PEDIATRIC HEMATOLOGY AND ONCOLOGY
Advancing pediatric health through innovative research.Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.
Indian Journal of Hematology and Blood Transfusion
Advancing Hematology: Unveiling Insights for Better Blood HealthIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
Hematology Transfusion and Cell Therapy
Elevating standards in cell therapy and transfusion science.Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.
Journal of Hematology
Elevating Hematology Through Collaborative ResearchThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.
Journal of Blood Medicine
Advancing Hematology: Unveiling Breakthroughs in Blood MedicineThe Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.
EUROPEAN JOURNAL OF HAEMATOLOGY
Connecting Experts in the Evolving Field of HematologyEUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.
AMERICAN JOURNAL OF HEMATOLOGY
Empowering Discoveries in Blood DisordersAmerican Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.
Hematology-American Society of Hematology Education Program
Elevating Standards in Hematology EducationHematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.
BONE MARROW TRANSPLANTATION
Advancing the Frontiers of Transplantation Science.BONE MARROW TRANSPLANTATION, published by SpringerNature, stands as a leading journal in the fields of Hematology and Transplantation, as evidenced by its recognition in the Q1 category for both disciplines according to 2023 rankings. With an impressive impact factor and notable Scopus rankings—7th out of 54 in Medicine Transplantation and 25th out of 137 in Medicine Hematology—this journal is instrumental for researchers and professionals dedicated to advancements in bone marrow transplantation practices and research. Established in 1986, the journal publishes original research, clinical studies, and reviews that push the boundaries of current knowledge, making it essential reading for those looking to stay abreast of the latest developments in the field. Although offering limited Open Access options, BONE MARROW TRANSPLANTATION reaches a broad audience and furthers a global dialogue on best practices and innovative approaches in transplantation medicine. Its address in London, UK positions it at the heart of international research collaboration, fostering connections among scientists, clinicians, and students alike.
Therapeutic Advances in Hematology
Fostering collaboration for a healthier tomorrow.Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.